CNBC March 20, 2023
Annika Kim Constantino

Key Points

– U.S. Food and Drug Administration staff on Monday said Biogen’s investigational ALS drug may have a “clinical benefit” on a rare and aggressive form of the disease.

– The staff made the conclusion in briefing documents ahead of a meeting on Wednesday when a panel of external advisors will discuss whether to recommend accelerated approval of Biogen’s drug tofersen for the treatment of a rare genetic form of ALS.

– The FDA is slated to make a final decision on whether to approve the drug on April 25.

U.S. Food and Drug Administration staff on Monday said Biogen’s investigational ALS drug may have a “clinical benefit” on a rare and aggressive form of the disease,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression
FDA Approves Roche’s Cobas Malaria Test, Designed to Screen for Malaria in Potential Blood Donors
Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval

Share This Article